Study to Assess the Safety and Pharmacokinetic (PK) of CTP-692 in Healthy Volunteers

Inclusion Criteria: * Healthy adult males and females between 18 and 55 years of age, inclusive * Body weight ≥ 55 kg and BMI within the range of 18 to 32 kg/m2, inclusive Exclusion Criteria: * Screening laboratory measurements outside the normal range associated with potential risk for the treatment under investigation at screening and/or prior to the first dose of study drug * Positive blood screen for human immunodeficiency virus (HIV antibody), hepatitis B virus surface antigen or hepatitis C virus antibody * History of clinically significant central nervous system (e.g., seizures), cardiac, pulmonary, metabolic, renal, hepatic or gastrointestinal (GI) conditions * Positive drug or alcohol test at screening or prior to the first dose of study drug